Introduction: Aberrant MAPK pathway signaling is a hallmark of melanoma.
Mitogen/extracellular signal-regulated kinase (MEK) 1/2 are integral components of MAPK …

The discovery of activating mutations in BRAF at high frequency in cutaneous melanoma
opened the door to new treatment options, which have resulted in significantly better patient …

PURPOSE In COLUMBUS part 1, patients with advanced BRAF V600-mutant melanoma
were randomly assigned 1: 1: 1 to encorafenib 450 mg once daily plus binimetinib 45 mg …

Opinion statement Melanoma is the most aggressive of the cutaneous malignancies,
causing more than 9,000 deaths in the past year in the United States. Historically, systemic …

Inhibitors of the mitogen-activated protein kinases (MAPK), BRAF, and MAP–ERK kinase
(MEK) induce tumor regression in the majority of patients with BRAF-mutant metastatic …

BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with
advanced V600E/K BRAF melanomas. Somatic activating MEK1 mutations are thought to be …

Approximately 50% of patients with cutaneous metastatic melanoma harbor a somatic BRAF
mutation. BRAF inhibitors are now established in the treatment paradigm of BRAF mutant …

Selective BRAF inhibitors have recently emerged as a new standard treatment for patients
with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase …

The MAPK pathway is frequently activated in many human cancers, particularly melanomas.
A single-nucleotide mutation in BRAF resulting in the substitution of glutamic acid for valine …

No head-to-head studies exist comparing BRAF inhibitor/MEK inhibitor (BRAFi/MEKi)
combination treatments for BRAF-mutant melanoma. A side-by-side analysis of randomized …